推荐产品
重组
expressed in HEK 293 cells
质量水平
抗体形式
purified immunoglobulin
抗体产品类型
primary antibodies
克隆
RM8, monoclonal
recombinant monoclonal
表单
buffered aqueous glycerol solution
种属反应性
human
浓度
~1 mg/mL
技术
ELISA: 0.5-2 μg/mL
immunoblotting: 0.5-2 μg/mL
immunocytochemistry: 0.5-5 μg/mL
immunohistochemistry: 0.5-5 μg/mL
同位素/亚型
IgG
NCBI登记号
UniProt登记号
运输
wet ice
储存温度
−20°C
靶向翻译后修饰
unmodified
基因信息
human ... BRAF(673)
一般描述
BRAF（B-Raf 原癌基因）是一种丝氨酸-苏氨酸激酶，编码 B-Raf 蛋白。它位于人类染色体7q34上。
特异性
该抗体与BRAF V600E突变体反应。与野生型BRAF无交叉反应。
免疫原
对应于BRAF V600E突变体的肽
生化/生理作用
BRAF（B-Raf 原癌基因）参与细胞生长的直接信号传导。它通过在皮肤黑色素瘤、甲状腺癌和结肠癌等各种肿瘤中启动丝裂原活化蛋白激酶 (MAPK) 途径，诱导肿瘤生长。
特点和优势
请完全放心地评估我们的抗体。如果抗体在您的研究中无效，我们将全额退款或换货。了解更多。
外形
溶于含有50％甘油、1％BSA和0.09％叠氮化钠的磷酸盐缓冲盐水中。
免责声明
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
未找到合适的产品？
试试我们的产品选型工具.
储存分类代码
10 - Combustible liquids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
常规特殊物品
含少量动物源组分生物产品
Xuhong Wang et al.
Oncology letters, 18(1), 927-935 (2019-07-11)
Keratin 19 (KRT19) is a type I cytokeratin that serves an important role in multiple types of cancer; however, little is known regarding its role in thyroid cancer. Therefore, the aim of the current study was to investigate the role
The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.
Hannan EJ, et al.
Medicine, 96(48), e8404-e8404 (2017)
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
Shinozaki E, et al.
British Journal of Cancer, 117(10), 1450-1450 (2017)
Daniel Delev et al.
Scientific reports, 10(1), 96-96 (2020-01-11)
Long-term epilepsy-associated tumors (LEATs) represent mostly benign brain tumors associated with drug-resistant epilepsy. The aim of the study was to investigate the specific transcriptional signatures of those tumors and characterize their underlying oncogenic drivers. A cluster analysis of 65 transcriptome
Maria Russi et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 180, 106311-106311 (2022-10-24)
Two clinically approved anticancer drugs targeting BRAF in melanoma patients - dabrafenib (DAB) and vemurafenib (VEM) - have been successfully encapsulated into nanomicelles formed upon self-assembly of an amphiphilic dendrimer AD based on two C18 aliphatic chains and a G2
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门